A clinical trial evaluating the therapeutic efficacy of pterostilbene, an MTA1 inhibitor, for the treatment of prostate cancer has been designed and is ongoing [Levenson, A.S. (2018) MTA1-targeted strategies for prostate cancer management. This evidence concerns the gene MTA1 and prostate cancer.